New hope for kids with HIV: shorter TB prevention studied
NCT ID NCT05122767
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study looks at how safe and effective a short, once-weekly treatment for latent tuberculosis (TB) is in children and teens with HIV who are taking the antiretroviral drug dolutegravir. The goal is to see if the TB drugs interact with the HIV medication and to check for side effects. About 92 participants aged 3 months to 17 years are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital
Klerksdorp, North West, 2571, South Africa
-
The Aurum Institute: Pretoria Clinical Research Centre
Pretoria, Gauteng, 0087, South Africa
Conditions
Explore the condition pages connected to this study.